Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, has entered into a contract manufacturing agreement with EDP Biotech, a medical device company focused on the development and commercialization of immunodiagnostic tests. Under terms of the 10-year agreement, Corgenix will manufacture and supply the ColoMarker diagnostic test, a blood test developed to detect the early stages of colon cancer. Corgenix recently announced the expansion of its Contract Services business unit and launched a dedicated Contract Services website.
EDP Biotech’s research into cancer biomarkers identified a protein biomarker shown to exist in elevated levels in colorectal cancer patients. The identification of this biomarker, known as CA11-19, was the key to developing ColoMarker, a simple blood test designed to identify potential cases of early stage colon cancer. The test requires no advance preparation by the patient such as fasting or colon cleansing, and it can be added easily to the panel of blood tests routinely performed at a patient’s annual physical exam.
“We are pleased to enter into this mutually beneficial relationship with EDP,” says Douglass Simpson, President and CEO of Corgenix. “This reflects our strategic focus on the Contract Services portion of our business for diagnostic products, and it meets the increasing demand overall for contract services in the medical device and biotechnology industries.” Learn more about this test.
